AbbVie will present Phase III TEMPLE study results at the 2025 International Headache Congress, showing atogepant’s superior tolerability and efficacy over topiramate for migraine prevention. Atogepant...
Teva initially got the chance to launch its drug called fremanezumab before Aimovig, but the opportunity slipped away when there was a delay in its FDA...